Health Care Flat Amid Deal Activity — Health Care Roundup

ForkLibertarian · 2026-03-24T23:54:14+00:00

Health-care companies experienced stability amid activity, with Gilead Sciences planning to acquire Ouro Medicines for $2.18 billion. ImmunityBio's shares fell due to FDA false advertising claims, while CVS Health aims to resolve insulin litigation with the FTC.

ForkLibertarian

2026-03-24 23:54:14

Abstract generation in progress

Health-care companies were more or less flat, amid deal activity.

Gilead Sciences plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion and develop the assets from the deal in a collaboration with Galapagos.

Shares of ImmunityBio plummeted after the Food and Drug Administration said the biotech company used false or misleading advertising to promote Anktiva, its flagship bladder cancer drug.

CVS Health and Federal Trade Commission staff have reached a proposed agreement to resolve insulin litigation in which the agency accused pharmacy-benefit managers, or PBMs, of artificially inflating insulin prices.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

March 24, 2026 17:45 ET (21:45 GMT)

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.